Please assess the completion status of the following clinical trial:

Trial Title: Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Patients must have diagnosis of breast cancer or non small cell lung cancer~* Patients must have evaluable disease~* Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study.~* Patients must have given signed, informed consent prior to registration on study.~Exclusion Criteria:~* Patients must not be pregnant and/or lactating.~* Patients must not be receiving any other investigational agents.~* No prior exposure to vinorelbine or other VEGF inhibitors as treatment for metastatic disease~* Patients must not have received prior therapy (including radiation, surgery, and/or chemotherapy) within 30 days~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or vinorelbine.~* Patients cannot have received more than 2 prior chemotherapy regimens for lung cancer or 3 prior chemotherapy regimens for breast cancer. This criterion can be discussed further with the study doctor.~* Must not have uncontrolled illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmic, psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pazopanib + Vinorelbine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).